Drug Approval | June 26, 2025
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
Globally, BRUKINSA is approved in more than 70 countries
Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme
If approved, linerixibat could address high unmet medical need of patients living with cholestatic pruritus (relentless itch) and related sleep interference
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Subscribe To Our Newsletter & Stay Updated
